Maxillary Sinus Elevation With Bio-Oss or Straumann BoneCeramic

NCT ID: NCT00901121

Last Updated: 2016-03-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

48 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-07-31

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to test a clinically relevant non-inferiority of Straumann BoneCeramic treatment compared to Bio-Oss treatment 180 to 240 days after sinus grafting procedure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, controlled, randomised, multicenter study. The total study duration for each patient should be three years.

In total 13 visits per patient are scheduled in this study.

The study device Straumann Bone Ceramic is CE-marked.

Height centers in Italy will participate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Teeth Loss Bone Loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BoneCeramic

Straumann BoneCeramic is a fully synthetic bone graft substitute of medical grade purity in particulate form composed of biphasic calcium phosphate - a mixture of 60% hydroxylapatite and of 40% of the beta form of tricalcium phosphate (beta-TCP).

Group Type EXPERIMENTAL

Straumann BoneCeramic

Intervention Type DEVICE

Straumann BoneCeramic (500-1000 microns, 0.5g)

Bio-Oss

Bio-Oss spongiosa granules, size of particle 0.25-1 mm

Group Type ACTIVE_COMPARATOR

Bio-Oss

Intervention Type DEVICE

Bio-Oss spongiosa granules, size of particle 0.25-1 mm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Straumann BoneCeramic

Straumann BoneCeramic (500-1000 microns, 0.5g)

Intervention Type DEVICE

Bio-Oss

Bio-Oss spongiosa granules, size of particle 0.25-1 mm

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males and females were at least 18 years of age and not more than 70 years old
* A dental implant procedure was foreseen in the maxilla region corresponding to maxillary sinus
* Patients presented a bone defect in the sinus area, which needed a sinus floor elevation to place one or more dental implants
* The patients were unilaterally or bilaterally edentulous in the maxillary region corresponding to the sinuses
* Residual alveolar crest height of the lateral-posterior segments of the edentulous maxilla below the floor of the maxillary sinus was less than 8 mm and at least 3 mm, measured by CT scans. Furthermore, residual alveolar crest width should be at least in average 6 mm measured by the CT scans
* Patients were committed to the study
* Patients were healthy at time of surgery

Exclusion Criteria

* Medical conditions requiring prolonged use of steroids
* Standard blood test performed by the medical practitioner of the patient showing: leukocyte dysfunction and deficiencies
* Haemophilia, bleeding disorders or cumarin therapy
* History of neoplastic disease requiring the use of chemotherapy
* History of radiation therapy to the head and neck
* Patients with history of renal failure or chronic renal diseases
* Patients affected by chronic liver diseases
* Patients with severe or uncontrolled metabolic bone disorders
* Uncontrolled endocrine disorders (including diabetes)
* Current pregnancy at the time of recruitment
* Physical handicaps that would interfere with the ability to perform adequate oral hygiene
* Use of any investigational drug or device within the 90 days period immediately prior to implant surgery on study day 0
* Alcoholism or chronically drug abuse causing systemic compromisation
* Immunocompromised patients including patients infected with HIV
* Patients who smoke more than 10 cigarettes per day or cigar equivalents, or who chew tobacco
* Conditions or circumstances, in the opinion of the investigator, which could represent a general contra-indication for surgical procedure or would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability


* Local inflammation, including untreated periodontitis to residual dentition
* Mucosal diseases such as erosive lichen planus
* History of local radiation therapy
* Presence of oral lesions (such as ulceration, malignancy)
* Severe bruxing or clenching habits
* Persistent intraoral infection
* Patients with inadequate oral hygiene or unmotivated for adequate home care
* Unhealed extraction sites in the upper premolar or molar area
* Last tooth extraction performed less than 3 months before surgery 1
* Previous GBR (guided bone regeneration) or dental implant treatment in the lateral-posterior segments of the upper maxilla (foreseen implant site)
* Patients presenting clinical and radiological signs and symptoms of maxillary sinus disease
* Patients presenting with residual alveolar crest height of the lateral-posterior segments of the edentulous maxilla below the floor of the maxillary sinus less than 3 mm and residual alveolar crest width less than 6 mm (measured by the CT scans)
* The reduction in residual bone height was determined by sinus pneumatization and not by vertical resorption of the residual alveolar crest with increased interarch distance. Patients with increased interarch distance were excluded from the study
* Existing teeth in the residual dentition with untreated endodontic or cariologic problems
* Horizontal or vertical augmentation to correct the vertical inter-arch distance or to correct horizontal defects
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Institut Straumann AG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matteo Chiapasco, Prof

Role: PRINCIPAL_INVESTIGATOR

University of Milan

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Private Practice

Milan, , Italy

Site Status

University of Milan

Milan, , Italy

Site Status

Private Practice

Naples, , Italy

Site Status

Private Practice

Naples, , Italy

Site Status

Private Practice

Pavia, , Italy

Site Status

Private Practice

Rome, , Italy

Site Status

Private Practice

Rome, , Italy

Site Status

Eastman Dental Hospital ASL RMA Roma

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

References

Explore related publications, articles, or registry entries linked to this study.

Cordaro L, Bosshardt DD, Palattella P, Rao W, Serino G, Chiapasco M. Maxillary sinus grafting with Bio-Oss or Straumann Bone Ceramic: histomorphometric results from a randomized controlled multicenter clinical trial. Clin Oral Implants Res. 2008 Aug;19(8):796-803. doi: 10.1111/j.1600-0501.2008.01565.x.

Reference Type RESULT
PMID: 18705811 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR 09/04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.